Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 15/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29653930 | 0.88 | NOTUM (0.61) | NOTUMARPGR | |
| SCHEMBL17110468 | 0.88 | NOTUM (0.61) | NOTUMARPGR | |
| SCHEMBL17672487 | 0.85 | NOTUM (0.57) | NOTUM | |
| SCHEMBL4952291 | 0.83 | PDK2 (0.49) | NOTUMARPGR | |
| SCHEMBL4193337 | 0.81 | AR (0.47) | ARPGR | |
| SCHEMBL17672598 | 0.81 | NOTUM (0.54) | NOTUMAR | |
| SCHEMBL17843509 | 0.81 | RXRA (0.55) | ARPGRRXRARXRBRXRG | |
| SCHEMBL8148281 | 0.80 | CA1 (0.52) | — | |
| SCHEMBL1997248 | 0.80 | NOTUM (0.73) | NOTUM | |
| SCHEMBL17672783 | 0.80 | NOTUM (0.52) | NOTUMAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590107-B2 | Cerium (IV) complexes and their use in organic electronics | Credoxys GmbH (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-4557929-A2 | CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | CREDOXYS GmbH (DE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4029069-B1 | CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | Credoxys GmbH (DE) | 2025-04-09 | — | — | EP | disclosed |
| US-20230092935-A1 | CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | Credoxys GmbH (DE) | 2023-03-23 | — | — | US | disclosed |
| EP-4029069-A1 | CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | Credoxys GmbH c/o Institut for Applied Physics (DE) | 2022-07-20 | — | — | EP | disclosed |
| CN-114364653-A | Cerium (IV) complexes and their use in organic electronic components | 克雷多西斯有限公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021048044-A1 | CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | Technische Universität Dresden (DE) | 2021-03-18 | — | — | WO | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | NOTUM 4067/4885AR 934/4885PGR 925/4885 |
| US-12590107-B2 | Cerium (IV) complexes and their use in organic electronics | CLIC4, CCR4, LOXL4 | NOTUM 1702/4885AR 3434/4885PGR 1671/4885 |
| US-20230092935-A1 | CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | CLIC4, KCNN4, CLN6 | NOTUM 264/4885AR 4437/4885PGR 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.